← Back to Search
Monoclonal Antibodies
ABBV-142 for Healthy Subjects
Grayslake, IL
Phase 1
Recruiting
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Must not have
History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 120
Summary
"This trial aims to understand how a new drug, ABBV-142, behaves in the body, its safety, how well it is tolerated, and how the immune system responds to it. The
See full description
Who is the study for?
This clinical trial is for healthy adults. Specific eligibility criteria are not detailed, but typically participants should have no significant medical conditions and be willing to comply with study procedures.Check my eligibility
What is being tested?
The trial is testing ABBV-142, a new medication given by subcutaneous injections or intravenous infusions. It's being compared to a placebo to see how the body processes it and if it's safe at effective doses.See study design
What are the potential side effects?
Possible side effects may include reactions at the injection site, general discomfort, allergic responses, or other unforeseen issues related to ABBV-142 or the infusion process.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I haven't had any serious illnesses, infections, fevers, hospital stays, or surgeries in the last 30 days.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to day 120
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 120
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
AUC of ABBV-142 from Time 0 to Infinity (AUCinf)
Area Under the Serum Concentration-time Curve (AUC) of ABBV-142 from Time 0 to the Time of Last Measurable Concentration (AUCt)
Dose Normalized AUC of ABBV-142
+6 moreTrial Design
9Treatment groups
Experimental Treatment
Group I: Part 3: Group 9Experimental Treatment2 Interventions
Japanese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.
Group II: Part 3: Group 8Experimental Treatment2 Interventions
Han Chinese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.
Group III: Part 2: Group 7Experimental Treatment2 Interventions
Participants will receive ABBV-142 Dose C or Placebo on Day 1.
Group IV: Part 2: Group 6Experimental Treatment2 Interventions
Participants will receive ABBV-142 Dose B or Placebo on Day 1.
Group V: Part 1: Group 5 (Optional)Experimental Treatment2 Interventions
Participants will receive ABBV-142 Dose TBD or Placebo on Day 1.
Group VI: Part 1: Group 4Experimental Treatment2 Interventions
Participants will receive ABBV-142 Dose D or Placebo on Day 1.
Group VII: Part 1: Group 3Experimental Treatment2 Interventions
Participants will receive ABBV-142 Dose C or Placebo on Day 1.
Group VIII: Part 1: Group 2Experimental Treatment2 Interventions
Participants will receive ABBV-142 Dose B or Placebo on Day 1.
Group IX: Part 1: Group 1Experimental Treatment2 Interventions
Participants will receive ABBV-142 Dose A or Placebo on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Find a Location
Closest Location:Acpru /Id# 271899· Grayslake, IL· 607 miles
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
AbbVieLead Sponsor
1,070 Previous Clinical Trials
532,454 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
484 Previous Clinical Trials
170,383 Total Patients Enrolled